These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3858802)

  • 1. Pharmacological properties of presynaptic dopamine receptor agonists.
    Carlsson A
    Psychopharmacology Suppl; 1985; 2():31-8. PubMed ID: 3858802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.
    Clark D; Hjorth S; Carlsson A
    J Neural Transm; 1985; 62(3-4):171-207. PubMed ID: 2863323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effect of the racemic mixture and the (-)enantiomer of N-n-propyl-3-(3-hydroxyphenyl)-piperidine (3-PPP) on postsynaptic dopamine receptors and on a presynaptic dopamine autoreceptor.
    Markstein R; Lahaye D
    J Neural Transm; 1983; 58(1-2):43-53. PubMed ID: 6317801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.
    Clark D; Hjorth S; Carlsson A
    J Neural Transm; 1985; 62(1-2):1-52. PubMed ID: 3894582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential electrophysiological effects of 3-PPP and its enantiomers on dopamine autoreceptors and postsynaptic receptors.
    Bergstrom DA; Carlson JH; Bromley SD; Jackson DM; Walters JR
    Eur J Pharmacol; 1986 May; 124(1-2):75-84. PubMed ID: 3720847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor agonists: intrinsic activity vs. state of receptor.
    Carlsson A
    J Neural Transm; 1983; 57(4):309-15. PubMed ID: 6418858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neurones.
    Kelly E; Jenner P; Marsden CD
    Neurosci Lett; 1985 May; 56(1):57-62. PubMed ID: 4011049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation.
    Hjorth S; Clark D; Carlsson A
    Eur J Pharmacol; 1988 Aug; 152(3):207-15. PubMed ID: 3146512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of (+/-)-3-PPP (3-(3-hydroxyphenyl)-1-n-propylpiperidine).
    Kelly TR; Howard HR; Koe BK; Sarges R
    J Med Chem; 1985 Sep; 28(9):1368-71. PubMed ID: 3928893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics.
    Rollema H; Mastebroek D; Wikström H; Svensson K; Carlsson A; Sundell S
    J Med Chem; 1986 Oct; 29(10):1889-95. PubMed ID: 3761308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
    Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
    Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC
    Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Psychopharmacology (Berl); 1983; 81(3):199-207. PubMed ID: 6139838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The search for selective dopaminergic autoreceptor agonists.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A; Nilsson JL
    J Neural Transm Suppl; 1983; 18():131-7. PubMed ID: 6576112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.
    Kreiss DS; Bergstrom DA; Gonzalez AM; Huang KX; Sibley DR; Walters JR
    Eur J Pharmacol; 1995 Apr; 277(2-3):209-14. PubMed ID: 7493610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes.
    Williams M; Totaro JA
    Eur J Pharmacol; 1982 Dec; 86(1):35-42. PubMed ID: 7160432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.